+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Embryonic Stem Cells Market - Global Forecast 2026-2032- Product Image
Human Embryonic Stem Cells Market - Global Forecast 2026-2032- Product Image
Sale

Human Embryonic Stem Cells Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674543
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Embryonic Stem Cells Market is projected to reach USD 2.83 Billion in 2026. It is expected to continue growing at a CAGR of 11.03%, reaching USD 5.35 Billion by 2032.

Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner cell mass of the blastocyst and remain central to regenerative medicine, developmental biology, drug discovery, disease modeling, and toxicology screening. Since the first successful derivation of human embryonic stem cell lines in 1998, hESC platforms have helped researchers study early human development and generate differentiated cell types, including cardiomyocytes, retinal pigment epithelial cells, pancreatic progenitors, neurons, and hepatocyte-like cells.

The human embryonic stem cells market is shaped by demand for high-quality pluripotent stem cell models, reproducible cell differentiation protocols, GMP-grade cell manufacturing, and translational research in cell therapy. Growth is also supported by advances in xeno-free culture systems, single-cell analysis, genome editing, organoid platforms, and automated quality control. At the same time, ethical review, donor consent, embryo-use regulations, and cross-border variability in policy remain defining considerations for commercial strategy and research adoption.

Transformative Shifts in the hESC Landscape

The hESC landscape is shifting from exploratory academic research toward more standardized, translational, and quality-controlled platforms. Laboratories and manufacturers are prioritizing feeder-free and xeno-free media, defined extracellular matrices, validated differentiation workflows, and release-testing standards that support reproducibility, cell identity confirmation, sterility assurance, genomic stability, and regulatory readiness.

Another major transformation is the movement from two-dimensional culture toward organoids, assembloids, microphysiological systems, and high-content screening. These systems improve physiological relevance for drug discovery and disease modeling while reducing dependence on animal models. Strategic collaborations among universities, biotechnology developers, contract development and manufacturing organizations, and hospital-based translational centers are accelerating the path from pluripotent stem cell biology to clinical-grade applications.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator for human embryonic stem cell research. AI-enabled image analysis supports colony morphology assessment, pluripotency monitoring, contamination detection, and differentiation-stage classification. Machine learning is also being used to interpret single-cell RNA sequencing, proteomics, epigenomics, and high-content imaging data, helping researchers identify lineage trajectories and optimize differentiation conditions.

The cumulative impact is greater process control across research and manufacturing. AI can reduce manual variability, improve batch comparability, predict culture failures earlier, and support more efficient experimental design. For hESC-derived therapeutics, AI-driven analytics can strengthen potency assays, cell identity verification, and safety screening, although all AI outputs still require biological validation, data governance, and alignment with regulatory expectations for explainability, auditability, and traceability.

Key Regional Insights

Asia-Pacific is a highly dynamic region for human embryonic stem cells, with Japan, China, South Korea, India, Australia, and ASEAN economies investing in regenerative medicine, stem cell banking, cell therapy infrastructure, precision medicine, and biomanufacturing capabilities. Japan is recognized for regenerative medicine policy innovation and pluripotent stem cell science, China is expanding translational research and clinical infrastructure, South Korea has strong cell therapy and bioprocessing capabilities, India is strengthening quality oversight, and Australia contributes through high-quality biomedical research networks.

North America remains a leading region for hESC research due to its concentration of biomedical universities, NIH-supported research infrastructure, private biotechnology investment, and clinical trial networks. The United States drives much of the region’s translational activity through established regulatory oversight for cell and gene therapies, while Canada contributes through regenerative medicine networks, ethics governance, and collaborative research programs. Latin America is emerging through Brazil and Mexico, where academic research, public health priorities, and healthcare modernization are expanding opportunities, although infrastructure depth and regulatory maturity vary across countries.

Europe is supported by advanced academic centers, the European Medicines Agency’s advanced therapy medicinal product framework, and country-specific approaches to embryo research. Germany, France, Italy, Spain, and the United Kingdom maintain strong biomedical ecosystems, though legal permissions, funding conditions, and ethical review processes differ by jurisdiction. The Middle East is investing in advanced healthcare hubs, genomics, and biomanufacturing, particularly in GCC states, while Africa remains earlier-stage for hESC commercialization, with research partnerships, academic capacity building, and interest in affordable regenerative medicine platforms gradually increasing regional relevance.

Key Group Insights

Within ASEAN, Singapore is a regional anchor for biomedical research, GMP manufacturing, and translational science, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are building clinical research capacity and healthcare innovation ecosystems. The GCC is increasing investment in life sciences, precision medicine, genomics, and hospital-based innovation, creating opportunities for stem cell research partnerships and future advanced therapy infrastructure.

The European Union offers a structured regulatory pathway for advanced therapy medicinal products and strong research funding mechanisms, but hESC rules are not fully uniform across member states, making country-level compliance essential. BRICS economies combine large patient populations, expanding biotechnology sectors, and rising government support for advanced medical research, with China, India, and Brazil particularly active in regenerative medicine, cell biology, and translational research capacity building.

G7 countries represent the most mature concentration of biomedical funding, intellectual property generation, regulatory expertise, clinical translation capacity, and advanced therapy manufacturing infrastructure. NATO member countries overlap heavily with North American and European innovation hubs, where defense-related biomedical research, trauma medicine, tissue repair, radiation injury research, and biomanufacturing resilience can support broader stem cell technology development.

Key Country Insights

The United States leads in hESC-related research output, biotechnology formation, venture funding, and clinical translation infrastructure, supported by major universities, the NIH ecosystem, and established FDA oversight for cell and gene therapies. Canada is known for regenerative medicine networks and strong translational collaboration, while Mexico is developing capabilities through academic medicine, private healthcare, and cross-border research opportunities. Brazil is Latin America’s most visible market for stem cell science, supported by major research universities and public health relevance.

The United Kingdom remains influential through stem cell governance, life sciences clusters, and clinical trial capacity. Germany, France, Italy, and Spain contribute strong biomedical research, cell therapy expertise, and advanced therapy manufacturing capabilities, with country-specific ethical and legal frameworks shaping hESC activity. Russia maintains scientific capacity in cell biology and regenerative medicine research, although international collaboration conditions, funding access, and regulatory alignment influence market participation.

China is rapidly expanding stem cell research, biomanufacturing, and translational medicine, while India combines a large scientific talent base, cost-effective research capacity, and growing regulatory attention to cell therapy quality. Japan is globally recognized for regenerative medicine policy innovation and pluripotent stem cell science, Australia contributes through high-quality biomedical research and clinical networks, and South Korea remains a strong hub for cell therapy, bioprocessing, and life sciences manufacturing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize ethically sourced, well-characterized hESC lines with documented donor consent, traceability, karyotype stability, pluripotency markers, sterility testing, mycoplasma testing, and pathogen screening. Investment in xeno-free, feeder-free, and GMP-compatible workflows can reduce translational risk and improve readiness for partnerships, licensing, technology transfer, and regulatory submissions.

Organizations should integrate AI-enabled quality analytics, single-cell multi-omics, automated imaging, digital batch records, and validated data governance early in development. Strategic collaborations with academic centers, CDMOs, hospital networks, ethics committees, and regulatory experts can accelerate differentiation protocol validation, potency assay design, comparability studies, and clinical trial planning. Leaders should also monitor country-specific embryo research laws, patentability rules, biobanking requirements, and import-export controls to avoid delays in global commercialization.

Research Methodology

This executive summary is developed using a structured secondary-research approach focused on publicly available and verifiable sources, including regulatory agency guidance, peer-reviewed scientific literature, clinical trial registries, institutional stem cell resources, government funding information, and international biotechnology policy references. Emphasis is placed on evidence-based interpretation rather than unsupported market sizing, market share calculation, or forecasting.

The methodology evaluates scientific maturity, regulatory environment, ethical governance, translational readiness, manufacturing infrastructure, regional investment patterns, and adoption of enabling technologies such as AI, organoids, CRISPR-based research tools, and single-cell analytics. Insights are triangulated across multiple source categories to support reliable market analysis for the human embryonic stem cells industry.

Conclusion

Human embryonic stem cells continue to play a foundational role in regenerative medicine, disease modeling, developmental biology, and high-value drug discovery. Their ability to generate specialized human cell types gives the field long-term relevance, particularly as cell therapy, organoid systems, microphysiological models, and precision toxicology become more central to biomedical innovation.

The market’s next phase will be defined by ethical governance, regulatory clarity, automated quality control, AI-enabled analytics, and scalable GMP manufacturing. Organizations that combine scientific rigor with transparent compliance, validated data systems, and strong regional strategy will be best positioned to capture opportunities in the evolving human embryonic stem cells market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Embryonic Stem Cells Market, by Product
7.1. Introduction
7.2. Accessories And Consumables
7.2.1. Accessories
7.2.2. Consumables
7.3. Differentiation Reagents
7.3.1. Growth Factor Kits
7.3.2. Small Molecule Reagents
7.4. Human Embryonic Stem Cell Culture Media
7.4.1. Serum Based
7.4.2. Serum Free
7.5. Human Embryonic Stem Cell Lines
7.5.1. Clinical Grade
7.5.2. Research Grade
7.6. Serums And Growth Factors
7.6.1. Growth Factors
7.6.2. Serum
8. Human Embryonic Stem Cells Market, by Indication
8.1. Introduction
8.2. Cardiovascular Disorders
8.2.1. Heart Failure
8.2.2. Ischemic Heart Disease
8.3. Diabetes
8.3.1. Type 1 Diabetes
8.3.2. Type 2 Diabetes
8.4. Neurological Disorders
8.4.1. Alzheimers Disease
8.4.2. Parkinsons Disease
8.5. Orthopedic Disorders
8.5.1. Bone Regeneration
8.5.2. Cartilage Repair
9. Human Embryonic Stem Cells Market, by Technology
9.1. Introduction
9.2. Allogeneic Hesc
9.3. Autologous Hesc
10. Human Embryonic Stem Cells Market, by Application
10.1. Introduction
10.2. Basic Research
10.3. Clinical Research
10.4. Drug Discovery And Development
10.4.1. Target Screening
10.4.2. Toxicity Screening
10.5. Regenerative Medicine
10.5.1. Cell Therapy
10.5.2. Tissue Engineering
10.6. Toxicology Testing
11. Human Embryonic Stem Cells Market, by End User
11.1. Introduction
11.2. Academic And Research Institutes
11.3. Contract Research Organizations
11.4. Hospitals And Clinics
11.5. Pharmaceutical And Biotechnology Companies
11.5.1. Biotechnology Companies
11.5.2. Pharmaceutical Companies
12. Human Embryonic Stem Cells Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Human Embryonic Stem Cells Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Human Embryonic Stem Cells Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Astellas Pharma Inc.
16.2. ATCC
16.3. BD Biosciences
16.4. Bio-Techne Corporation
16.5. BlueRock Therapeutics, Inc.
16.6. Cell Engineering Corporation
16.7. Cellartis AB
16.8. Corning Incorporated
16.9. Cynata Therapeutics Limited
16.10. GE Healthcare Life Sciences
16.11. Lineage Cell Therapeutics, Inc.
16.12. Lonza Group Ltd.
16.13. Merck KGaA
16.14. Miltenyi Biotec GmbH
16.15. Organovo Holdings, Inc.
16.16. PeproTech, Inc.
16.17. Pluri Inc.
16.18. PromoCell GmbH
16.19. R&D Systems, Inc.
16.20. STEMCELL Technologies Inc.
16.21. Takara Bio Inc.
16.22. Thermo Fisher Scientific, Inc.
16.23. ViaCyte, Inc.
List of Figures
FIGURE 1. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACCESSORIES AND CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ACCESSORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ACCESSORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ACCESSORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DIFFERENTIATION REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GROWTH FACTOR KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULE REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HUMAN EMBRYONIC STEM CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SERUM BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SERUM BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SERUM BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SERUM FREE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SERUM FREE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SERUM FREE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL HUMAN EMBRYONIC STEM CELL LINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CLINICAL GRADE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CLINICAL GRADE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CLINICAL GRADE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL RESEARCH GRADE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RESEARCH GRADE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL RESEARCH GRADE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SERUMS AND GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ISCHEMIC HEART DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ALZHEIMERS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PARKINSONS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ORTHOPEDIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL BONE REGENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BONE REGENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BONE REGENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ALLOGENEIC HESC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AUTOLOGOUS HESC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TARGET SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL TARGET SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL TARGET SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL TOXICITY SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL TOXICITY SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL TOXICITY SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 159. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 161. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 162. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 163. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 164. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 165. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 166. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 167. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 168. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 169. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 170. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 171. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 172. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 174. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 175. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. EUROPE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 213. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 214. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 215. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 216. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 217. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 218. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 219. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 220. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 222. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 223. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 224. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 225. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 226. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 227. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 228. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 229. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 249. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 252. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 253. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 254. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 255. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 256. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 257. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 259. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 260. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 261. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 262. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 263. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 264. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 265. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 266. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. NATO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 268. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 270. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 271. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 272. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 273. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 274. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 275. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 276. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 277. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 278. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 279. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 280. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 281. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 282. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 283. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 284. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. G7 HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 286. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 288. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 289. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 290. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 291. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 292. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 293. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 294. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 295. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 296. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 297. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 298. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 299. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 300. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 301. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 302. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. BRICS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ORTHOPEDIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2017-2032 (USD MILLION)
TABLE 322. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 323. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 324. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 325. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY DIFFERENTIATION REAGENTS, 2017-2032 (USD MILLION)
TABLE 326. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL CULTURE MEDIA, 2017-2032 (USD MILLION)
TABLE 327. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL LINES, 2017-2032 (USD MILLION)
TABLE 328. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY SERUMS AND GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 329. ASEAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 330. ASEAN HU

Companies Mentioned

  • Astellas Pharma Inc.
  • ATCC
  • BD Biosciences
  • Bio-Techne Corporation
  • BlueRock Therapeutics, Inc.
  • Cell Engineering Corporation
  • Cellartis AB
  • Corning Incorporated
  • Cynata Therapeutics Limited
  • GE Healthcare Life Sciences
  • Lineage Cell Therapeutics, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Organovo Holdings, Inc.
  • PeproTech, Inc.
  • Pluri Inc.
  • PromoCell GmbH
  • R&D Systems, Inc.
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.83 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.35 Billion
Compound Annual Growth Rate11.0%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Human Embryonic Stem Cells Market Report 2026 - Product Image

Human Embryonic Stem Cells Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Human Embryonic Stem Cell (hESC) Research - Global Strategic Business Report - Product Image

Human Embryonic Stem Cell (hESC) Research - Global Strategic Business Report

  • Report
  • 184 Pages
  • Global
From
Human Embryonic Stem Cells - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Human Embryonic Stem Cells - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Stem Cells Market - Global Forecast 2026-2032 - Product Image

Stem Cells Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Human Organoids Market - Global Forecast 2026-2032 - Product Image

Human Organoids Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From

About the Embryonic Stem Cell Market

The Embryonic Stem Cell (ESC) market is a subset of the larger stem cell market. ESCs are derived from embryos and are pluripotent, meaning they can differentiate into any cell type in the body. They are used in research to study the development of cells and tissues, and in regenerative medicine to replace damaged or diseased cells. ESCs are also used in drug discovery and development, as they can be used to test the safety and efficacy of new drugs. The ESC market is highly regulated, as the use of embryos is controversial. Regulations vary by country, and some countries have banned the use of ESCs altogether. Despite this, the ESC market is growing, driven by advances in stem cell research and the potential for regenerative medicine. Companies in the ESC market include Cellular Dynamics International, Pluristem Therapeutics, and Stem Cell Therapeutics. These companies are involved in the research, development, and commercialization of ESCs for therapeutic and research applications. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.